Back to Search
Start Over
Path Less Traveled: Targeting Rare Driver Oncogenes in Non-Small-Cell Lung Cancer.
- Source :
-
JCO oncology practice [JCO Oncol Pract] 2024 Jan; Vol. 20 (1), pp. 47-56. Date of Electronic Publication: 2023 Sep 21. - Publication Year :
- 2024
-
Abstract
- Over the past decade, tremendous efforts have been made in the development of targeted agents in non-small-cell lung cancer (NSCLC) with nonsquamous histology. Pivotal studies have used next-generation sequencing to select the patient population harboring oncogenic driver alterations that are targetable with targeted therapies. As treatment paradigm rapidly evolves for patients with rare oncogene-driven NSCLC, updated comprehensive overview of diagnostic approach and treatment options is paramount in clinical settings. In this review article, we discuss the epidemiology, molecular testing, and landmark clinical trials addressing the targeted agents for ROS1 rearrangement, METex14 skipping mutation, EGFR exon 20 insertion, KRAS G12C mutation, HER2 mutation, RET fusion, NTRK fusion, and BRAF mutations.<br />Competing Interests: Yuko OyaHonoraria: Chugai Pharma, AstraZeneca, Lilly, Bristol Myers Squibb Japan, Amgen, Takeda, Daiichi Sankyo/UCB Japan, MSDConsulting or Advisory Role: Lilly Sun Min LimResearch funding: AstraZeneca, BeiGene, BMS, Boehringer-Ingelheim, Bridge BioTherapeutics, Daichii-Sankyo, Gilead, GSK, Jiangsu Hengrui Medicine, J Ints Bio, Oscotec, Roche, YuhanAdvisory role: AstraZeneca, Boehringer-Ingelheim, BMS, Lilly, Janssen, Takeda, Daiichi-Sankyo, Yuhan, Guardant Jii Bum LeeHonoraria: Astra Zeneca, Takeda, Boehringer Ingelheim, Amgen, Merck, Janssen, Guardant, MSDResearch Funding: Yuhan Ross SooHonoraria: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Lilly, Novartis, Pfizer, Roche/Genentech, Takeda, Yuhan, Amgen, Bayer, Merck, Merck Serono, Puma Biotechnology, J INTS BIOConsulting or Advisory Role: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Pfizer, Roche/Genentech, Taiho Pharmaceutical, Yuhan, Takeda, Amgen, Lilly, Merck, Janssen, Puma Biotechnology, Merck Serono, Bayer, Thermo Fisher Scientific, J INTS BIOResearch Funding: AstraZeneca, Boehringer IngelheimNo other potential conflicts of interest were reported.
Details
- Language :
- English
- ISSN :
- 2688-1535
- Volume :
- 20
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- JCO oncology practice
- Publication Type :
- Academic Journal
- Accession number :
- 37733983
- Full Text :
- https://doi.org/10.1200/OP.23.00273